Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
A legfontosabb adatok
- Ki végzi
- Institute of Hematology & Blood Diseases Hospital, China
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 52 fő, tervezett
- Kezdés
- 2021. szept. 1.
- Tervezett befejezés
- 2025. szept. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Avatrombopag
- A regiszteradat frissítve
- 2025. február 24.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with immune thrombocytopenia (ITP, low platelets caused by the immune system) with autoantibodies. Eltrombopag or herombopag must not have worked, or could not be taken.
- Életkor
- 18 years and older
- Nem
- Men and women
- A betegség stádiuma
- ITP linked to connective tissue disease (such as lupus, Sjogren's syndrome or rheumatoid arthritis), ITP with a positive antinuclear antibody test, Evans syndrome, or ITP with a positive Coomb's test. Platelet count below 30 ×10^9/L at screening.
- Korábbi kezelés
- Eltrombopag (75 mg/d) or Herombopag (7.5 mg/D) for at least 4 weeks did not work or stopped working, or could not be used, tolerated or was refused. Other ITP treatment must be finished, or stable or being lowered within 2 weeks before joining. No rituximab within 3 months.
- Biomarker vagy leletérték
- Autoantibodies: positive antinuclear antibody or positive Coomb's test, or a connective tissue disease.
A részvétel fő kizáró okai
- Avatrombopag did not work before (40mg once a day for more than 4 weeks)
- Blood clot within 3 months with risk factors, or use of blood thinners or antiplatelet drugs
- Spleen removal within 3 months or planned within 3 months
- Lupus affecting the brain or kidneys, cataract, or active infection
- Pregnant or breastfeeding women, or planning pregnancy during the trial
A regiszter feltételei, szó szerint
Mind a 26 feltétel megnézéseKevesebb
Ki vehet részt
- The patients have provided written informed consent prior to enrollment
- Men and women greater than or equal to 18 years of age
- Diagnosed as ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome
- Platelet count<30 ×10\^9/L at screening
- Patients who have previously failed to receive Eltrombopag or Herombopag [poor efficacy (Eltrombopag 75 mg/d or Herombopag 7.5 mg/D, at least 4 weeks), or the efficacy cannot be maintained], or who have contraindications, can not tolerate or refuse Eltrombopag or Herombopag treatment
- Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, and other thrombopoietin receptor agonists other than Avatrombopag) must be completed before enrollment, or the dose must be stable or in a phase of reduction within 2 weeks before enrollment
- Effective contraceptive measures will be taken during the clinical trial
Ki nem vehet részt
- Patients with any prior history of arterial or venous thrombosis within 3 months, and with any of the following risk factors: cancer, Factor V Leiden, ATIII deficiency, or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening
- Those who had received rituximab within 3 months
- Patients who had failed to respond to the previous use of Avatrombopag (40mg once a day for more than 4 weeks)
- Patients who had received splenectomy within 3 months or have splenectomy plan within 3 months
- There are surgical planners during the study
- Patients that had participated in other experimental researches within one month before enrollment
- Patients with active thyroid disease requiring treatment
- Subjects known to be allergic to Avatrombopag or any of its excipients
- Patients with infectious fever (including but not limited to pulmonary infection) within 1 month or with active infection during screening
- Existing hepatitis B virus, hepatitis C virus replication or HIV infection
- Patients with severe cardiac or pulmonary dysfunction
- History of psychiatric disorder
- Patients with a history of drug/alcohol abuse (within 2 years before the study)
- Severe liver dysfunction (alanine aminotransferase or glutamic oxaloacetic transaminase > 3×ULN)
- Severe renal damage (creatinine clearance < 30 ml/min)
- Patients with lupus encephalopathy or lupus nephritis
- Patients with cataract
- Pregnant or lactating women or those planning to be pregnant during the trial
- Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.
A vizsgálat csoportja
- Treatment groupA vizsgált kezelés
Fifty-two subjects will be enrolled with the indicated treatment dose of avatrombopag
Kezelés: Avatrombopag
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2025. február 24.